<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02967939</url>
  </required_header>
  <id_info>
    <org_study_id>DA2802_HB_III</org_study_id>
    <nct_id>NCT02967939</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients</brief_title>
  <official_title>Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802(Tenofovir Disoproxil Orotate) and Viread®(Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study demonstrates the non-inferiority of DA-2802 when compared with ㅍViread® in chronic
      hepatitis B patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. DA-2802 319mg Group: Administration with DA-2802 319mg tablet qd and placebo tablet
           matching to Viread® 300mg for 0-48 weeks.

        2. Viread® 300mg Group: Administration with Viread® 300mg tablet qd and placebo tablet
           matching to DA-2802 319mg for 0-48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of HBV DNA level(log10)</measure>
    <time_frame>Change from baseline at 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects HBV DNA &lt; 400 copies/ml</measure>
    <time_frame>at 24 weeks, 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who had normal ALT levels</measure>
    <time_frame>at 24 week, 48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who experienced loss of HBeAg</measure>
    <time_frame>at 24 week, 48 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis B， Chronic</condition>
  <arm_group>
    <arm_group_label>DA-2802</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-2802 319mg tablet qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viread®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Viread® 300mg tablet qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-2802</intervention_name>
    <description>DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.</description>
    <arm_group_label>DA-2802</arm_group_label>
    <other_name>tenofovir disoproxil orotate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viread®</intervention_name>
    <description>Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.</description>
    <arm_group_label>Viread®</arm_group_label>
    <other_name>tenofovir disoproxil fumarate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic hepatitis B aged 18 years or older

          -  Subjects who have evidence to demonstrate a history of chronic hepatitis B for at
             least six months from the time of screening visit

          -  Subjects who have HBsAg positive test at screening visit

          -  Subjects who did not receive the hepatitis B treatment, including interferon or
             pegylated interferon, within 24 weeks of starting the screening test

          -  Subjects with an ALT of 80 units or more and 10 times lower than the normal upper
             limit at the time of screening

        Exclusion Criteria:

          -  Subjects infected with hepatitis C, hepatitis D or human immunodeficiency virus

          -  Subjects with creatinine clearance of less than 50 ml/min at the screening visit

          -  At the time of screening visit, alpha-fetoprotein level was higher than 50 ng/ml and
             related imaging test showed hepatocellular carcinoma

          -  Subjects with decompensated liver disease who meet the following criteria:

               1. Total bilirubin levels greater than 2.5 mg/dl

               2. Prothrombin time is at least 3 seconds longer than normal upper limit

               3. Serum albumin value less than 30 g/l

               4. Subjects with a history of ascites, jaundice, bleeding from varicose veins,
                  hepatic encephalopathy, or other signs of liver failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong eun Yeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jong eun Yeon, M.D., Ph.D</last_name>
    <phone>+82-2-2626-3010</phone>
    <email>jeyyeon@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Eun Yeon, Ph D.</last_name>
      <phone>+82-2-2626-3010</phone>
      <email>jeyyeon@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

